Day 1 –Wednesday, 23 Sept 2026Wednesday, September 23, 2026 - ET (Eastern Time, GMT-05:00)

The biopharma industry stands at the cusp of a transformative era, fueled by unprecedented advancements in science, technology, and global partnerships. Artificial intelligence is reshaping drug discovery and clinical trials, unlocking efficiencies and possibilities that were once unimaginable Emerging markets, particularly China, are becoming key players in the global biopharma ecosystem, presenting new opportunities for partnerships, innovation, and patient-centric solutions. This panel will convene industry leaders to discuss how biopharma can navigate these challenges, harness emerging opportunities, and deliver life-changing treatments to patients worldwide.

• Exploring high-growth regions and their potential for biopharma innovation

• Understanding the role of government policies and incentives in emerging markets

• Identifying key investment drivers and challenges in global biopharma expansion

The biotech industry is undergoing a paradigm shift, driven by the rapid evolution of emerging therapeutic modalities and groundbreaking scientific advancements. From RNA-based therapies and gene editing technologies to the promise of precision medicine and regenerative treatments, these innovations are reshaping the landscape of healthcare. This panel will explore the transformative potential of these modalities, addressing the scientific, regulatory, and commercial challenges that come with scaling novel therapies. Attendees will gain insights into how biotech leaders are leveraging cutting-edge platforms, forging strategic collaborations, and navigating complex ecosystems to deliver next-generation solutions that meet the evolving needs of patients worldwide.

• The rise of RNA-based therapies and gene editing technologies: Opportunities, challenges, and their impact on disease treatment paradigms

• Precision medicine and its role in tailoring therapies to individual patients: Scientific breakthroughs and commercialization strategies

• Regenerative medicine and cell-based therapies: Scaling access, overcoming manufacturing hurdles, and addressing ethical considerations

• Streamlining the journey from research to clinical application

• Overcoming regulatory and operational hurdles in drug development

• Enhancing patient access to life-saving therapies through innovation

• Securing funding and strategic partnerships to bridge critical gaps

• Building robust preclinical data to attract investors and collaborators

• Navigating regulatory pathways to accelerate development timelines

• Fundable milestones: TPP to trancheable proof (MoA, biomarkers, CMC) with kill gates and burn discipline.

• Capital mix: Seed/Series A + non-dilutive + venture debt + pharma options; avoid value-draining terms.

• Build model: Studio vs. independent; virtual vs. in-house; tight CRO/CDMO oversight and lean talent/SABs beyond legacy hubs.

• How can translational science be embedded earlier to validate biomarkers and human-relevant models?
• How can clinician–scientist co-design better align endpoints, patient selection, and implementation?
• How can real-world evidence and pragmatic studies be used to refine interventions and accelerate clinical uptake?

Biotech is moving from momentum to precision—where disciplined design, clean data, and sharp value inflections matter as much as breakthrough ideas. The next chapter favors teams that build capital efficiency into the science itself: right-sized studies, decisive biomarkers, and data packages that travel. This panel explores how to architect programs, partnerships, and pipelines that outperform across market cycles while staying true to transformational patient impact.

• Designing for investability: stage gates, prespecified criteria, and crisp inflection points that align scientific progress with capital allocation

• Partnership architectures that de-risk: co-development with pharma and tech, platform-to-asset spin-outs, and non-dilutive funding to extend runway

• Pipelines by conviction: narrowing to first- or best-in-class bets, using adaptive trials and biomarker strategies to accelerate proof and preserve optionality

Mergers and acquisitions have long been a cornerstone of growth and innovation in the biopharma industry, enabling companies to expand pipelines, access new technologies, and strengthen market positions. This panel will delve into real-world case studies of successful biopharma M&A deals, uncovering the key drivers and strategies that led to their success. Attendees will gain valuable insights into navigating integration challenges, optimizing post-merger synergies, and fostering value creation through innovation. By examining lessons learned from these transformative deals, the discussion will provide actionable takeaways for leveraging M&A as a strategic tool to drive growth and deliver impactful solutions to patients.

• Key drivers and strategies behind successful biopharma M&A deals

• Lessons learned from integration challenges and post-merger synergies

• Insights into value creation and innovation through M&A in the biopharma sector